Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Several other brokerages also recently commented on IMUX. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Price Performance

Shares of IMUX stock opened at $1.09 on Tuesday. Immunic has a one year low of $0.97 and a one year high of $2.11. The company’s fifty day moving average price is $1.14 and its 200-day moving average price is $1.32. The company has a market capitalization of $98.19 million, a price-to-earnings ratio of -0.89 and a beta of 1.88.

Insiders Place Their Bets

In other news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunic

Several large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter valued at $50,000. Jane Street Group LLC grew its stake in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.